A A Kulesh

Plain English
This study looked at the use of the drug Fortelyzin to treat patients who had an acute ischemic stroke (AIS) when they received treatment between 4.5 and 24 hours after their symptoms started. Researchers found that 61% of patients treated within the first 4.5 hours had a good recovery, while 65% of those treated later also had a good recovery, showing that treatment is still effective even when started later. The rates of serious complications were similar in both groups, indicating that Fortelyzin is a safe option for stroke patients, regardless of when they receive treatment. Who this helps: This helps stroke patients who may not get to the hospital within the first few hours of their symptoms.

Plain English
This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings. Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.

Plain English
This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options. Who this helps: Patients with acute ischemic stroke and their healthcare providers.

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

Plain English
The study compared two treatments for ischemic stroke: non-immunogenic staphylokinase (NS) and alteplase (AP). It found that NS was faster to administer (17 minutes compared to 38 minutes for AP), led to fewer patients suffering brain damage (46% with NS vs. 61% with AP), and resulted in better neurological recovery, as indicated by a lower NIHSS score. This matters because quicker and more effective treatment can lead to better outcomes for stroke patients. Who this helps: Stroke patients.

Plain English
This study looked at 114 patients aged 18 to 55 who had ischemic stroke due to a condition called paradoxical embolism, which is linked to a heart defect known as patent foramen ovale (PFO). Researchers found that among patients at the Research Center of Neurology, 93% had PFO as a likely cause of their strokes, compared to only 51% of patients at the other hospital. This matters because it shows that more thorough testing is needed to accurately identify the underlying causes of strokes in these patients, as relying on initial screenings can lead to misdiagnosis. Who this helps: This helps patients with ischemic stroke and doctors in diagnosing and treating their condition.

Plain English
This study focused on improving prevention strategies for patients at high risk of severe strokes due to blood vessel issues. Researchers found that using a combination of certain medications, like aspirin with clopidogrel or ticagrelor for short-term treatment, and aspirin with rivaroxaban for long-term care, can significantly lower the chances of having another stroke or dying—potentially reducing these risks by up to 30% in high-risk individuals. This matters because it offers better protection for vulnerable patients and helps doctors make more informed treatment decisions. Who this helps: High-risk stroke patients and their healthcare providers.

Plain English
The COMPASS study looked at how a combination of rivaroxaban (2.5 mg twice a day) and acetylsalicylic acid (100 mg per day) can help prevent repeated non-coronary ischemic strokes. The findings showed that this combination is effective and safe for patients. This matters because it offers a new treatment option that can help reduce the risk of future strokes in certain patients. Who this helps: Patients at risk of recurrent non-coronary ischemic strokes.

Plain English
This study focuses on familial hemiplegic migraine (FHM), a rare type of migraine that affects about 0.01% of people. Researchers looked at a family where both a father and daughter experienced severe headaches, nausea, vomiting, and symptoms like visual disturbances and weakness on one side of their bodies, confirming their diagnosis of FHM. Understanding this condition is important because it helps identify appropriate treatments and increase awareness among healthcare providers. Who this helps: This helps patients and their families coping with hemiplegic migraine.

Plain English
This study focuses on a condition called cerebrovascular disease with neurocognitive impairment, which includes various forms of brain damage due to blood flow problems. It highlights how this condition can lead to issues with thinking and memory, especially after a stroke. The findings stress the importance of diagnosing this condition early so that treatment can slow down its progression and potentially reduce the chances of having a stroke or developing dementia. Who this helps: Patients experiencing cognitive issues after strokes and their doctors.

Plain English
This study looked at two main causes of sudden dizziness: strokes in certain parts of the brain and vestibular neuritis, which affects balance. The researchers found that identifying which condition someone has is crucial because treatment differs significantly—treatments for vestibular neuritis and strokes vary greatly, and the study provides a clear plan for doctors to help diagnose and treat these conditions accurately. This matters because getting the right treatment can prevent further complications and improve recovery. Who this helps: This helps doctors who treat patients with sudden dizziness and those patients themselves.

Plain English
This study details a case of a 14-year-old who experienced familial temporal lobe epilepsy with vertigo-related seizures. The researchers discovered a mutation in the CPA6 gene that helped confirm the diagnosis, despite other tests like brain scans showing no significant abnormalities. Understanding this specific condition is important because it helps identify and treat similar cases more effectively. Who this helps: This benefits patients and their doctors by providing clearer diagnoses for those with rare epilepsy types.

Plain English
This study looked at two young women under 40 who were diagnosed with CADASIL syndrome, a genetic condition that can be confused with multiple sclerosis (MS) based on symptoms and MRI results. It found that many doctors aren’t recognizing the differences between CADASIL and MS, which can lead to misdiagnoses. Understanding these differences is important because getting the right diagnosis will ensure patients receive the appropriate treatment and care. Who this helps: This helps patients with CADASIL syndrome and their doctors.

Plain English
This study looked at patients with severe strokes to see how effective and safe the treatment called thrombolysis is. Out of 274 patients analyzed, those who received thrombolysis showed better results: 0.7% experienced bleeding issues, while those treated had a higher rate of good outcomes and improved mobility after leaving the hospital. This is important because it highlights the value of quick treatment in helping patients recover from strokes more effectively. Who this helps: This helps patients who suffer from ischemic strokes, as well as doctors treating them.

Plain English
This study looked at the role of melatonin in cognitive problems that can occur after a stroke, comparing older patients (ages 61-86) and middle-aged patients (ages 36-60). Researchers found that older patients had lower levels of a melatonin byproduct called 6-sulfatoximelatonin compared to younger patients, and this low level was linked to worse cognitive performance. Specifically, the higher the melatonin level, the worse the cognitive impairment was among older stroke patients. Who this helps: This information benefits healthcare providers and caregivers of elderly patients recovering from strokes.

Plain English
This study looked at different types of cognitive issues that can occur after a stroke and tried to identify specific brain markers that could help in understanding these conditions. Researchers assessed 72 patients and found that those with a specific type of cognitive impairment, called dysexecutive impairment, had higher levels of certain inflammatory proteins (like IL-1β and IL-6) and had more severe brain damage compared to those with normal cognition. Identifying these brain markers is important because it could lead to more targeted treatments for patients suffering from cognitive problems after a stroke. Who this helps: This helps patients recovering from strokes and their doctors in tailoring effective treatments.

Plain English
This study looked at the levels of specific proteins (cytokines) in the blood and spinal fluid of 70 patients who had a recent stroke. Researchers found that patients had higher levels of IL-10 compared to people without strokes, and those with higher IL-1β showed worse stroke outcomes and cognitive function. Understanding these relationships helps improve treatment and recovery strategies for stroke patients. Who this helps: Patients recovering from strokes.

Plain English
This study looked at how stroke affects thinking and memory in 288 patients who had an ischemic stroke. Researchers found that 87% of these patients experienced problems with attention, speech, and memory. They tested a drug called cellex on 30 patients and found it helped improve their cognitive functions significantly. Who this helps: This is beneficial for stroke patients who may have cognitive issues.

Plain English
This study looked at frontotemporal degeneration, a common cause of dementia in younger people. The researchers reported a specific case where the patient mainly struggled with speech due to this condition. They found that using a special type of brain imaging called diffusion tensor imaging (DTI) helps identify areas of brain damage and improves diagnosis, which is crucial since this disease often goes undiagnosed. Who this helps: This helps doctors in diagnosing frontotemporal degeneration more accurately.

Plain English
The study looked at 128 patients who had recently experienced an ischemic stroke, analyzing their characteristics and the effects of a drug called cellex. The researchers found that patients who received cellex showed better recovery, with a lower level of neurological problems and higher mobility compared to those who did not take the drug. This matters because finding effective treatments can significantly improve the lives of stroke patients and their ability to regain mobility. Who this helps: Patients recovering from ischemic stroke.

Plain English
This study looked at brain activity in patients with focal epileptic seizures between seizure episodes using a method called spectral analysis. It found that patients with these seizures had slower brain wave patterns, especially in certain areas of the brain, and showed differences in brain activity based on age and gender. Specifically, patients over 45 had unique changes in beta waves, and female patients had different delta waves. Who this helps: This research benefits patients with epilepsy and their doctors by providing insights into brain activity patterns related to focal seizures.

Plain English
This study looked at how a treatment called melaxen affects cognitive and emotional issues, as well as sleep quality in patients who have had a stroke. Researchers found that in 96 stroke patients, those with certain types of cognitive problems had lower levels of a melatonin-related substance in their urine, and using melaxen improved cognitive functions, sleep quality, and reduced anxiety. This is important because it shows that treating sleep and emotional issues immediately after a stroke can help the recovery process. Who this helps: This helps stroke patients by improving their recovery and quality of life.

Plain English
This study looked at the timing of strokes and the cognitive issues that follow by analyzing 80 patients with acute ischemic stroke. Researchers found that factors like sleep quality and social environment play a big role in recovery, and treating patients with melaxen (a sleep aid) led to improved recovery of sleep patterns and better rehabilitation outcomes. This matters because understanding how timing and treatment can affect stroke recovery can lead to better care for patients. Who this helps: Patients recovering from strokes.

Plain English
This study looked at the levels of a substance called 6-sulfatoxymelatonin in the urine of 57 patients experiencing acute strokes. Researchers found that those with ischemic strokes had lower levels of this substance at night, which linked to worse cognitive performance, higher anxiety levels, and poorer sleep quality. The findings suggest that melatonin deficiency might play a significant role in these problems after a stroke. Who this helps: This helps patients who have had a stroke and their healthcare providers.

Plain English
This study investigated the levels of certain substances in patients with acute ischemic stroke to see if they are linked to cognitive problems. Researchers found that lower amounts of melatonin (below 4.0 ng/ml in urine) and butyrylcholinesterase (below 7.0 nmol/L in blood) were associated with memory and overall cognitive issues. These findings help identify patients who may be at risk for cognitive impairments after a stroke, making it possible to address their needs more effectively. Who this helps: Patients recovering from ischemic stroke and their doctors.

Plain English
This study looked at 116 patients who experienced their first ischemic carotid stroke and had no previous issues with thinking or memory. Researchers found that while most patients performed well in areas like memory, 31% struggled with attention despite having good memory skills. The findings reveal different patterns of cognitive issues after a stroke, with 19% of patients facing significant memory problems, indicating that some may also be dealing with underlying neurodegenerative conditions. Who this helps: This helps patients recovering from stroke and their doctors in understanding and addressing cognitive challenges.